Sergio J. Dubner

TL;DR: In this paper, the authors systematically describe the >80% (83-100%, mean: 96%) required consensus achieved for each recommendation by official balloting in regard to the programming of bradycardia mode and rate, detection, tachycardia therapy, and intraprocedural testing of defibrillation efficacy.

TL;DR: The details in this document provide background and framework from which to apply AECG techniques in clinical practice, as well as clinical research.

TL;DR: This document systematically describes the >80% (83–100%, mean: 96%) required consensus achieved for each recommendation by official balloting in regard to the programming of (i) bradycardia mode and rate, (ii) tachycardia detection, (iii) tachedcardia therapy, and (iv) the intraprocedural testing of defibrillation efficacy.

TL;DR: The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) was designed to provide prospectively collected information on patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke, with the aim of addressing treatment patterns and questions of effectiveness and safety as discussed by the authors.

TL;DR: The GLORIA-AF is a large, international, observational registry involving patients with newly diagnosed nonvalvular AF at risk for stroke, enrolling up to 56,000 patients in nearly 50 countries and will add data from clinical practice to those from randomized trials to expand knowledge of antithrombotic treatment in patients with AF.